PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France LYON, France , Dec. 05, 2018 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment B -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH Partners with New York Blood Center for Red Blood Cell Supply and Research
LYON, France and CAMBRIDGE, Mass. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a strategic partnership with New
View HTML
Toggle Summary ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, November 13 at 14:30 CET/8:30 am EST Phase 3 trial for eryaspase in second line pancreatic cancer enrolling patients Phase 2 trial in triple-negative breast cancer to enroll patients by year end Cash position of €146.9 million ( $170 million ) as
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2018
LYON, France , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment B -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018
LYON, France and CAMBRIDGE, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a Key Opinion Leader (KOL)
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2018
LYON, France, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
LYON, France and CAMBRIDGE, Mass. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three
View HTML
Toggle Summary ERYTECH to Attend Upcoming Investor Conferences
LYON, France , Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that members of its management team will
View HTML
Toggle Summary ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, September 11 th at 2:30 pm CET / 8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmed Phase 3 trial for eryaspase in second line pancreatic cancer initiated and open for patient enrollment Phase 2 trial in
View HTML
Toggle Summary ERYTECH to Host Second Quarter 2018 Conference Call and Business Update
(GLOBE NEWSWIRE via COMTEX) --LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that
View HTML
Top